<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01997112</url>
  </required_header>
  <id_info>
    <org_study_id>PATHBP_2013</org_study_id>
    <secondary_id>PG/13/26/3012 8</secondary_id>
    <nct_id>NCT01997112</nct_id>
  </id_info>
  <brief_title>PAracetamol Treatment in Hypertension: Effect on Blood Pressure (PATH-BP) Study</brief_title>
  <acronym>PATH-BP</acronym>
  <official_title>PAracetamol Treatment in Hypertension: Effect on Blood Pressure (PATH-BP) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health Service, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine if chronic paracetamol dosing increases blood
      pressure in patients with known high blood pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomised, double-blind, crossover trial, comparing the effects of paracetamol
      1g (500mg x2) four times daily with matched placebo on ambulatory and clinic BP, each given
      for 14 days, with a 14-day washout period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">October 2019</completion_date>
  <primary_completion_date type="Actual">June 4, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic ambulatory blood pressure</measure>
    <time_frame>14 days</time_frame>
    <description>Difference in mean daytime systolic ambulatory BP between the paracetamol and placebo treated groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic clinic blood pressure</measure>
    <time_frame>14 days</time_frame>
    <description>Difference in systolic clinic BP between the paracetamol and placebo treated groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic ambulatory blood pressure</measure>
    <time_frame>14 days</time_frame>
    <description>Difference in mean daytime diastolic ambulatory BP between the paracetamol and placebo treated groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>paracetamol 1g (500mg x2) four times daily for 14 day period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo control: hard gelatin placebo capsules containing Lactose Ph Eur. Taken for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <arm_group_label>Paracetamol</arm_group_label>
    <other_name>Acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years old, men or post-menopausal women (women with no periods for 12 months or
             more, or those who have had a surgical menopause)

          -  Treated hypertensive patients with an average daytime ambulatory blood pressure
             measurement (ABPM) &lt;150/95mmHg on stable doses of one or more antihypertensive
             medication (at least one of which should be; an ACE inhibitor, angiotensin receptor
             blocker or diuretic) for 3 months, or untreated hypertensive patients with an average
             daytime ABPM ≥135/85 but &lt;150/95.

        Exclusion Criteria:

          -  History of ischaemic heart disease, cardiac failure, cerebrovascular disease, liver
             impairment (ALT/AST&gt;50IU/L) or stage 3-5 chronic kidney disease.

          -  History of overdose or suicidal ideation

          -  Patients weighing &lt;55kgs.

          -  Patients with chronic pain requiring treatment, with a known allergy to paracetamol,
             or concomitant use of non-steroidal anti-inflammatories , oral anticoagulants or
             corticosteroids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Centre, Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>City Of Edinburgh</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 21, 2013</study_first_submitted>
  <study_first_submitted_qc>November 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood pressure</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Paracetamol</keyword>
  <keyword>Acetaminophen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

